Frédéric Desmedt

ERC-Belgium SA is a Belgian clinical stage biopharmaceutical company that focuses on developing a safe and effective approach for treating cancer, particularly brain cancers. ERC's therapeutic approach is also being applied to a developmental vaccine against COVID-19 and can potentially be applied to many other types of solid cancers. The private company is based in Isnès, Belgium, with subsidiaries in the United States. The company has built a network of leading neuro-oncologists in several countries to propel its immunotherapies through clinical development and to market. ERC's therapeutic vaccines have shown early promise in patients suffering from recurrent glioblastoma multiforme (GBM), the deadliest of brain cancers. The company also provides products for patients who are not eligible for current clinical trials under the right to try law and other new programs established by different medical centers in the United States. ERC-Belgium was founded in 2008, and the CEO is Apostolos Stathopoulos.

Part of ERC-Belgium SA, Epitopoietic Research Corp. is a clinical stage emerging bio-pharmaceutical company based in Pasadena, CA. The company is developing a safe, highly effective approach for the treatment of cancer using immunotherapy, with particular focus on the treatment of patients with glioblastoma multiforme (GBM), the most deadliest form of brain cancer, using its patented Gliovac/ERC1671 vaccine. The company was founded by Bernard Alliaume, Apostolos Stathopoulos. Apostolos Stathopoulos has been the CEO since incorporation.